Eicosanoid mediators of mast cells: Receptors, regulation of synthesis, and pathobiologic implications

Chemical Immunology and Allergy

Volumn 87, Issue , 2005, Pages 59-79

  Boyce, Joshua A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; ALLERGEN; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; ARACHIDONIC ACID; COLLAGEN; CYTOKINE; EICOSANOID RECEPTOR; G PROTEIN COUPLED RECEPTOR; ICOSANOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 3; IONOPHORE; LEUKOTRIENE C4; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MONTELUKAST; PEPTIDOLEUKOTRIENE; PHOSPHOLIPASE A2; PRANLUKAST; PROSTAGLANDIN D2; PROTEIN KINASE C DELTA; RAMATROBAN; RECEPTOR; THROMBOXANE A2; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; VERLUKAST; ZAFIRLUKAST; ZYMOSAN; LEUKOTRIENE;

ALLERGY; ANTIGEN PRESENTATION; ASTHMA; BASOPHIL; BIOSYNTHESIS; BRAIN; BRONCHOSPASM; BRONCHUS MUSCLE; CELL ACTIVATION; CELL MATURATION; CELL MIGRATION; DENDRITIC CELL; DISEASE MODEL; ENDOTHELIUM CELL; EOSINOPHIL; FIBROSIS; GUINEA PIG; HEART; HELMINTH; HISTOPATHOLOGY; HOST RESISTANCE; HUMAN; ILEUM; INFLAMMATION; INTESTINE MUCOSA; LEUKOCYTE; LIGAND BINDING; LUNG FIBROSIS; LUNG LAVAGE; MACROPHAGE; MAST CELL; MICROPHTHALMIA; MONOCYTE; MOUSE STRAIN; NEMATODE; NEUTROPHIL; NIPPOSTRONGYLUS BRASILIENSIS; NONHUMAN; PATHOLOGY; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT STRAIN; REVIEW; RODENT; SMOOTH MUSCLE; STOMACH; SYNTHESIS; T LYMPHOCYTE; TH2 CELL; UTERUS; ANIMAL; BIOLOGICAL MODEL; DRUG EFFECT; IMMUNOLOGY; METABOLISM; MOUSE;

ANIMALS; CYTOKINES; EICOSANOIDS; HUMANS; LEUKOTRIENES; MAST CELLS; MICE; MODELS, BIOLOGICAL; PROSTAGLANDIN D2; RECEPTORS, EICOSANOID;

EID: 25144503991     PISSN: 16602242     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000087571     Document Type: Review

References (120)

1. Echtenacher B, Mannel DN, Hultner L: Critical protective role of mast cells in a model of acute septic peritonitis. Nature 1996;381:75-79.
2. Donaldson LE, Schmitt E, Huntley JF, Newlands GF, Grencis RK: A critical role for stem cell factor and c-kit in host protective immunity to an intestinal helminth. Int Immunol 1996;8:559-567.
3. Casale TB, Wood D, Richerson HB, Zehr B, Zavala D, Hunninghake GW: Direct evidence of a role for mast cells in the pathogenesis of antigen-induced bronchoconstriction. J Clin Invest 1987;80:1507-1515.
4. Lawrence ID, Warner JA, Cohan VL, Hubbard WC, Kagey-Sobotka A, Lichtenstein LM: Purification and characterization of human skin mast cells. Evidence for human mast cell heterogeneity. J Immunol 1987;139:3062-3069.
5. MacGlashan DW Jr, Schleimer RP, Peters SP, Schulman ES, Adams GK III, Newball HH, Lichtenstein LM: Generation of leukotrienes by purified lung mast cells. J Clin Invest 1982;70:747-751.
6. Peters SP, MacGlashan DW Jr, Schulman ES, Schleimer RP, Hayes EC, Rokach J, Adkinson NF Jr, Lichtenstein LM: Arachidonic acid metabolism in purified human lung mast cells. J Immunol 1984;132:1972-1979.
7. Fox CC, Dvorak AM, Peters SP, Kagey-Sobotka A, Lichtenstein LM: Isolation and characterization of human intestinal mucosal mast cells J Immunol 1985;135:483-491.
8. 4 and BLT1 control cytotoxic effector T cell recruitment to inflamed tissues. Nat Immunol 2003;4:963-975.
9. 2+-dependent translocation domain with homology to PKC and GAP. Cell 1992;65:1043-1051.
10. 2 via ATP in articular chondrocytes. J Biol Chem 2003;278:13680-13687.
11. 2 in FcεRI signaling to cysteinyl leukotriene synthesis in mast cells. J Immunol 2004;173:624-631.
12. 2 is essential for both the immediate and the delayed phases of eicosanoid generation in mouse bone marrow-derived mast cells. Proc Natl Acad Sci USA 1999;96:4803-4807.
13. 2 in mouse bone marrow-derived mast cells. J Biol Chem 1994;269:22269-222754.
14. Urade Y, Ujihara M, Horiguchi Y, Igarashi M, Nagata A, Ikai K, Hayaishi O: Mast cells contain spleen-type prostaglandin D synthetase. J Biol Chem 1990;265:371-375.
15. Urade Y, Fujimoto N, Hayaishi O: Purification and characterization of rat brain prostaglandin D synthetase. J Biol Chem 1985;260:12410-12415.
16. Lu R, Kanai N, Bao Y, Schuster VL: Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA (hPGT). J Clin Invest 1996;98:1142-1149.
17. 2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 1995;83:813-819.
18. 2 metabolite, as a sensitive marker of mast cell activation by allergen in bronchial asthma. Thorax 2004;59:459-464.
19. 2 into human airways during acute antigen challenge. N Engl J Med 1986;315:800-804.
20. Wenzel SE, Westcott JY, Smith HR, Larsen GL: Spectrum of prostanoid release after bronchoalveolar allergen challenge in atopic asthmatics and in control groups: An alteration in the ratio of bronchoconstrictive to bronchoprotective mediators. Am Rev Respir Dis 1989;139:450-457.
21. 2 in normal and asthmatic men. N Engl J Med 1984;311:209-213.
22. 2 potentiates airway responsiveness to histamine and methacholine. Am Rev Respir Dis 1986;133:252-254.
23. 4) in human skin. J Invest Derm 1983;80:115-119.
24. Roberts LJ 2nd, Turk JW, Oates JA: Shock syndrome associated with mastocytosis: Pharmacologic reversal of the acute episode and therapeutic prevention of recurrent attacks. Adv Shock Res 1982;8:145-152.
25. Hirata M, Kakizuka A, Aizawa M, Ushikubi F, Narumiya S: Molecular characterization of a mouse prostaglandin D receptor and functional expression of the cloned gene. Proc Natl Acad Sci USA 1994;91:11192-11196.
26. Boie Y, Sawyer N, Slipetz DM, Metters KM, Abramovitz M: Molecular cloning and characterization of the human prostanoid DP receptor. J Biol Chem 1995;270:18910-18916.
27. 2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 2001;193:255-261.
28. 2 receptor, CRTH2. Br J Pharmacol 2002;137:1163-1172.
29. Yoshimura-Uchiyama C, Iikura M, Yamaguchi M, Nagase H, Ishii A, Matsushima K, Yamamoto K, Shichijo M, Bacon KB, Hirai K: Differential modulation of human basophil functions through prostaglandin D receptors DP and chemoattractant receptor-homologous molecule expressed on Th2 cells/DP2. Clin Exp Allergy 2004;34:1283-1290.
30. 2 receptors CRTH2 and DP. J Allergy Clin Immunol 2001;108:982-988.
31. 2 affects the maturation of human monocyte-derived dendritic cells: Consequence on the polarization of naive Th cells. J Immunol 2003;170:4943-4952.
32. 2- and histamine-induced bronchoconstriction in asthma, and relationship to plasma drug concentration. Br J Clin Pharmacol 1992;34:2-8.
33. 2α. J Pharmacol Exp Ther 1997;281:957-964.
34. 2, a stable thromboxane metabolite, is a full agonist of chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2) in human eosinophils and basophils. J Biol Chem 2004;279:7663-7670.
35. 2-induced eosinophil migration in vitro. J Pharmacol Exp Ther 2003;305:347-352.
36. 2-induced bronchoconstriction is mediated only in part by the thromboxane prostanoid receptor. Eur Respir J 1995;8:411-415.
37. Fujitani Y, Kanaoka Y, Aritake K, Uodome N, Okazaki-Hatake K, Urade Y: Pronounced eosinophilic lung inflammation and Th2 cytokine release in human lipocalin-type prostaglandin D synthase transgenic mice. J Immunol 2002;168:443-449.
38. 2 reinforces Th2 type inflammatory responses of airways to low-dose antigen through bronchial expression of macrophage-derived chemokine. J Exp Med 2003;198:533-543.
39. 2 as a mediator of allergic asthma. Science 2000;287:2013-2017.
40. 2 inhibits airway dendritic cell migration and function in steady state conditions by selective activation of the D prostanoid receptor 1. J Immunol 2003;171:3936-3940.
41. 2 receptor-mediated functions. J Exp Med 2004;199:1317-1330.
42. Malavia R, Malavia R, Jakschik BA: Reversible translocation of 5-lipoxygenase in mast cells upon IgE/antigen stimulation. J Biol Chem 1993;268:4939-4944.
43. Dixon RA, Diehl RE, Opas E, Rands E, Vickers PJ, Evans JF, Gillard JW, Miller DK: Requirement of a 5-lipoxygenase-activating protein for leukotriene biosynthesis. Nature 1990;343:282-284.
44. 4 hydrolase from rat neutrophils. Biochim Biophys Acta 1985;840:43-50.
45. 4. Proc Natl Acad Sci USA 1994;91:7663-7669.
46. 4 by human eosinophils. J Biol Chem 1989;264:12885-12891.
47. 4 and structurally related conjugates. J Biol Chem 1994;269:27807-27810.
48. 4 and γ-glutamyl amino acids. Proc Natl Acad Sci USA 1982;79:1088-1091.
49. Carter BZ, Shi ZZ, Barrios R, Lieberman MW: Gamma-glutamyl leukotrienase, a γ-glutamyl transpeptidase gene family member, is expressed primarily in the spleen. J Biol Chem 1998;273:28277-28285.
50. 4 by a dipeptidase released from the specific granules of human polymorphonuclear leukocytes. Immunol 1983;48:27-35.
51. 4 from the urine of patients with airway obstruction. Am Rev Respir Dis 1992;146:104-108.
52. 4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am Rev Respir Dis 1990;142:112-119.
53. Dahlen SE, Hedqvist P, Hammarstrom S, Samuelsson B: Leukotrienes are potent constrictors of human bronchi. Nature 1980;288:484-486.
54. Hanna CJ, Bach MK, Pare PD, Schellenberg RR: Slow-reacting substances (leukotrienes) contract human airway and pulmonary vascular smooth muscle in vitro. Nature 1981;290:343-344.
55. Findlay SR, Lichtenstein LM, Siegel H, Triggle DJ: Mechanisms of contraction induced by partially purified slow reacting substance from human polymorphonuclear leukocytes and leukotriene D in guinea pig ileal smooth muscle. J Immunol 1981;126:1728-1730.
56. 4 in normal and asthmatic subjects. Am Rev Respir Dis 1987;135:333-337.
57. 4 and granulocytic infiltration into asthmatic airways. Lancet 1993;341:989-990.
58. Lynch KR, O'Neill GP, Liu Q, Im DS, Sawyer N, Metters KM, Coulombe N, Abramovitz M, Figueroa DJ, Zeng Z, Connolly BM, Bai C, Austin CP, Chateauneuf A, Stocco R, Greig GM, Kargman S, Hooks SB, Hosfield E, Williams DL Jr, Ford-Hutchinson AW, Caskey CT, Evans JF: Characterization of the human cysteinyl leukotriene cysLT1 receptor. Nature 1999;399:789-793.
59. Heise CE, O' Dowd BF, Figueroa DJ, Sawyer N, Nguyen T, Im DS, Stocco R, Bellefeuille JN, Abramovitz M, Cheng R, Williams DL Jr, Zeng Z, Liu Q, Ma L, Clements MK, Coulombe N, Liu Y, Austin CP, George SR, O'Neill GP, Metters KM, Lynch KR, Evans JF: Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem 2000;275:30531-30536.
60. 1) receptor. Biochem Pharmacol 2001;62:1193-1200.
61. 2) receptor: cDNA and genomic cloning, alternative splicing, and in vitro characterization. J Biol Chem 2001;276:47489-47495.
62. Figueroa DJ, Breyer RM, Defoe SK, Kargman S, Daugherty BL, Waldburger K, Liu Q, Clements M, Zeng Z, O'Neill GP, Jones TR, Lynch KR, Austin CP, Evans JF: Expression of the cysteinyl leukotriene 1 receptor in normal human lung and peripheral blood leukocytes. Am J Respir Crit Care Med 2001;163:226-233.
63. Figueroa DJ, Borish L, Baramki D: Philip G, Austin CP, Evans JF: Expression of cysteinyl leukotriene synthetic and signalling proteins in inflammatory cells in active seasonal allergic rhinitis. Clin Exp Allergy 2003;33:1380-1388.
64. 2 receptor accounts for calcium signaling by cysteinyl leukotrienes in human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol 2003;23:37-41.
65. 4 on human airway smooth muscle cell proliferation, matrix expression, and contraction in vitro: Differential sensitivity to cysteinyl leukotriene receptor antagonists. Am J Respir Cell Mol Biol 1998;19:453-461.
66. 4. J Allergy Clin Immunol 2003;111:1032-1040.
67. Mita H, Hasegawa M, Saito H, Akiyama K: Levels of cysteinyl leukotriene receptor mRNA in human peripheral leucocytes: Significantly higher expression of cysteinyl leukotriene receptor 2 mRNA in eosinophils. Clin Exp Allergy 2001;31:1714-1723.
68. Thivierge M, Stankova J, Rola-Pleszczynski M: IL-13 and IL-4 up-regulate cysteinyl leukotriene 1 receptor expression in human monocytes and macrophages. J Immunol 2001;167:2855-2860.
69. Mellor EA, Austen KF, Boyce JA: Cysteinyl leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human mast cells. Proc Natl Acad Sci USA 2001;98:7964-7969.
70. Mellor EA, Frank N, Soler D, Jora JM, Hodge MR, Austen KF, Boyce JA: Expression of the type 2 cysteinyl leukotriene receptor by human mast cells: Demonstration of function distinct from that of CysLTR1. Proc Natl Acad Sci USA 2003;100:11589-11593.
71. Mellor EA, Austen KF, Boyce JA: Cysteinyl leukotrienes and uridine diphosphate induce cytokine generation by human mast cells through an interleukin-4-regulated pathway that is inhibited by leukotriene receptor antagonists. J Exp Med 2002;195:583-592.
72. 4 are mediated by the 7-transmembrane receptor CysLT1. Blood 2001;97:3433-3440.
73. Bandeira-Melo C, Woods LJ, Phoofolo M, Weller PF: Intracrine cysteinyl leukotriene receptor-mediated signaling of eosinophil vesicular transport-mediated interleukin-4 secretion. J Exp Med 2002;196:841-850.
74. Israel E, Cohn J, Dube L, Drazen JM: Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. JAMA 1996;275:931-936.
75. Altman LC, Munk Z, Seltzer J, Noonan N, Shingo S, Zhang J, Reiss TF: A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. J Allergy Clin Immunol 1998;102:50-56.
76. Yoshida S, Ishizaki Y, Shoji T, Onuma K, Nakagawa H, Nakabayashi M, Akahori K, Hasegawa H, Amayasu H: Effect of pranlukast on bronchial inflammation in patients with asthma. Clin Exp Allergy 2000;30:1008-1014.
77. Hamilton A, Faiferman I, Stober P, Watson RM, O'Byrne PM: Pranlukast, a cysteinyl leukotriene receptor antagonist, attenuates allergen-induced early- and late-phase bronchoconstriction and airway hyperresponsiveness in asthmatic subjects. J Allergy Clin Immunol 1998;102:177-186.
78. Melo RE, Sole D, Naspitz CK: Exercise-induced bronchoconstriction in children: Montelukast attenuates the immediate-phase and late-phase responses. J Allergy Clin Immunol 2003;111:301-307.
79. Richter K, Jorres RA, Magnussen H: Efficacy and duration of action of the antileukotriene zafirlukast on cold air-induced bronchoconstriction. Eur Respir J 2000;15:693-699.
80. Rorke S, Jennison S, Jeffs JA, Sampson AP, Arshad H, Holgate ST: Role of cysteinyl leukotrienes in adenosine 5(-monophosphate induced bronchoconstriction in asthma. Thorax 2002;57:323-327.
81. Camargo CA Jr, Smithline HA, Malice MP, Green SA, Reiss TF: A randomized controlled trial of intravenous montelukast in acute asthma. Am J Respir Crit Care Med 2003;167:528-533.
82. 4 synthase. J Biol Chem 2001;276:22608-22613.
83. Martin TR, Gerard NP, Galli SJ, Drazen JM: Pulmonary responses to bronchoconstrictor agonists in the mouse. J Appl Physiol 1988;64:2318-2323.
84. Richter M, Sirois P: Effects of eicosanoids, neuromediators and bioactive peptides on murine airways. Eur J Pharmacol 2000;389:225-234.
85. Maekawa A, Austen KF, Kanaoka Y: Targeted gene disruption reveals the role of cysteinyl leukotriene 1 receptor in the enhanced vascular permeability of mice undergoing acute inflammatory responses. J Biol Chem 2002;277:20820-20824.
86. Beller TC, Maekawa A, Friend DS, Austen KF, Kanaoka Y: Targeted gene disruption reveals the role of the cysteinyl leukotriene 2 receptor in increased vascular permeability and in bleomycin-induced pulmonary fibrosis in mice. J Biol Chem 2004;279:46129-46134.
87. Irvin CG, Tu YPO, Sheller JR, Funk CD: 5-Lipoxygenase products are necessary for ovalbumin-induced airway responsiveness in mice. Am J Physiol 1997;272:L1053-L1058.
88. Henderson W, Lewis DB, Albert RK, Zhang Y, Lamm WJE, Chiang GKS, Jones F, Erikson P, Tien YT, Jonas M, Chi EY: The importance of leukotrienes in airway inflammation in a mouse model of asthma. J Exp Med 1997;184:1483-1494.
89. 2 in allergic response and parturition. Nature 1997;390:618-622.
90. Henderson WR, Tang LO, Chu SJ, Tsao SM, Chiang GKS, Jones F, Jonas M, Pae C, Wang H, Chi EY: A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am J Respir Crit Care Med 2002;165:108-116.
91. 4 transporter MRP1 regulates CCL19 (MIP-3β, ELC)-dependent mobilization of dendritic cells to lymph nodes. Cell 2000;103:757-768.
92. Machida I, Matsuse H, Kondo Y, Kawano T, Saeki S, Tomari S, Obase Y, Fukushima C, Kohno S: Cysteinyl leukotrienes regulate dendritic cell functions in a murine model of asthma. J Immunol 2004;172:1833-1838.
93. 2 in bleomycin-induced pulmonary fibrosis. Nat Med 2002;8: 480-484.
94. Peters-Golden M, Bailie M, Marshall T, Wilke C, Phan SH, Toews GB, Moore BB: Protection from pulmonary fibrosis in leukotriene-deficient mice. Am J Respir Crit Care Med 2002;165:229-235.
95. Finkelman FD, Shea-Donohue T, Goldhill J, et al: Cytokine regulation of host defense against parasitic gastrointestinal nematodes. Annu Rev Immunol 1997;15:505-533.
96. Ruitenberg EJ, Elgersma A: Absence of intestinal mast cell response in congenitally athymic mice during Trichinella spiralis infection. Nature (Lond) 1976;264:258-260.
97. Irani AM, Craig S, DeBlois G, Elson CO, Schechter NM, Schwartz LB: Deficiency of the tryptase-positive, chymase-negative mast cell type in gastrointestinal mucosa of patients with defective T lymphocyte function. J Immunol 1987;138:4381-4386.
98. Laitinen LA, Laitinen A, Haahtela T: Airway mucosal inflammation even in patients with newly diagnosed asthma. Am Rev Respir Dis 1993;147:697-704.
99. Anderson DF, MacLeod JD, Baddeley SM, Bacon AS, McGill JI, Holgate ST, Roche WR: Seasonal allergic conjunctivitis is accompanied by increased mast cell numbers in the absence of leukocyte infiltration. Clin Exp Allergy 1997;27:1060-1066.
100. Amin K, Rinne J, Haahtela T, Simola M, Peterson CG, Roomans GM, Malmberg H, Venge P, Seveus L: Inflammatory cell and epithelial characteristics of perennial allergic and nonallergic rhinitis with a symptom history of 1 to 3 years' duration. J Allergy Clin Immunol 2001;107:249-257.
101. Straumann A, Bauer M, Fischer B, Blaser K, Simon HU: Idiopathic eosinophilic esophagitis is associated with a Th2-type allergic inflammatory response. J Allergy Clin Immunol 2002;108:954-961.
102. Lantz CS, Boesiger J, Song CH, et al: Role for interleukin-3 in mast cell and basophil development and in immunity to parasites. Nature (Lond) 1998;392:90-93.
103. Madden KB, Urban JF Jr, Ziltener HJ, et al: Antibodies to IL-3 and IL-4 suppress helminth-induced intestinal mastocytosis. J Immunol 1991;147:1387-1391.
104. Temann UA, Geba GP, Rankin JA, Flavell RA: Expression of interleukin-9 in the lungs of transgenic mice causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness. J Exp Med 1998;188:1307-1320.
105. Ochi H, Hirani WM, Yuan Q, et al: T helper type-2 cytokine-mediated comitogenic responses and CCR3 expression during differentiation of human mast cells in vitro. J Exp Med 1999;190:267-280.
106. Bischoff SC, Sellge G, Lorentz A, et al: IL-4 enhances proliferation and mediator release in mature human mast cells. Proc Natl Acad Sci USA 1999;96:8080-8085.
107. Yanagida M, Fukamachi H, Ohgami K, et al: Effects of T-helper 2-type cytokines, interleukin (IL)-3, IL-4, IL-5, and IL-6 on the survival of cultured human mast cells. Blood 1995;86:3705-3714.
108. 2 by immunologically activated rat intestinal mucosa mast cells. J Immunol 1988;140:1953-1957.
109. Massey WA, Guo CB, Dvorak AM, Hubbard WC, Bhagavan BS, Cohan VL, Warner JA, Kagey-Sobotka A, Lichtenstein LM: Human uterine mast cells. Isolation, purification, characterization, ultrastructure, and pharmacology. J Immunol 1991;147:1621-1627.
110. MacGlashan DW Jr, Schleimer RP, Peters SP, Schulman ES, Adams GK III, Newball NH, Lichtenstein LM: Generation of leukotrienes by purified human lung mast cells. J Clin Invest 1982;70:747-751.
111. 2 generation in immature mouse mast cells. J Biol Chem 1995;270:3239-3246.
112. 2 in mouse bone marrow-derived mast cells. J Biol Chem 1994;269:22269-22275.
113. Zhang G, Ghosh S: Toll-like receptor-mediated NF-κ activation: A phylogenetically conserved paradigm in innate immunity. J Clin Invest 2001;107:13-19.
114. Supajatura V, Ushio H, Nakao A, Akira S, Okumura K, Ra C, Ogawa H: Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity. J Clin Invest 2002;109:1351-1359.
115. Rhee SH, Hwang D, Murine Toll-like receptor 4 confers lipopolysaccharide responsiveness as determined by activation of NFκB and expression of the inducible cyclooxygenase. J Biol Chem 2000;275:34035-34040.
116. 2 in human and rat mast cell lines. J Biol Chem 2003;278:4725-4729.
117. 2 in mouse mast cells. J Biol Chem 2004;279:48923-48929.
118. Kitamura Y, Go S, Hatanaka K: Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation. Blood 1978;52:447-452.
119. 4 synthase pathway in mouse mast cells. J Biol Chem 1995;270:22653-22656.
120. 4 synthase expression by interleukin-4. J Exp Med 2001;193:123-133.